Introduction
============

The human biogenic amine transporters (BATs) represent important drug targets for the treatment of many psychiatric diseases such as depression, anxiety, obesity, drug abuse, obsessive compulsive disorder, attention deficit hyperactive disorder, and schizophrenia ([@B26]; [@B22]; [@B18]; [@B36]; [@B11]; [@B59]; [@B34]; [@B19]). They are also the target of psychostimulants such as amphetamine, cocaine, and ecstasy ([@B44]; [@B47]; [@B13]). The BATs includes the serotonin (SERT), dopamine (DAT), and norepinephrine (NET) transporters, responsible for re-uptake of the neurotransmitters SERT, DAT, and NET, respectively and they function by terminating synaptic signaling ([@B46]; [@B42]; [@B33]). When blocking these proteins, the concentration of the neurotransmitter within the synapse is elevated hereby relieving the symptoms of many psychiatric diseases.

Rational design of drugs targeting the BATs has been difficult due to the lack of high resolution structural information. However, since 2005, when the first protein crystal structure of a protein belonging to this family of transporters, the bacterial leucine transporter from *Aquifex aeolicus*, LeuT, was published ([@B66]), homology modeling of the monoamine neurotransmitter transporters has been possible. The structure of LeuT revealed an architecture consisting of 12 transmembrane α-helixes (TMs) with both the N- and C-terminal placed intracellular and a centrally placed substrate binding site (known as S1) in the transmembrane part of the proteins, close to two sodium ion binding sites, Na1 and Na2, respectively ([@B66]). The structure furthermore revealed a structural repeat between TM1-TM5 and TM6-TM10 linked by a pseudo C2-rotation axis perpendicular to the membrane normal. This inverted repeat ([@B17]) is now commonly known as the LeuT-fold and is found in a broad class of proteins, which in addition to BATs also include Mhp1 ([@B64]; [@B55]), BetP ([@B43]), CaiT ([@B50]; [@B60]), AdiC ([@B15]), vSGLT ([@B14]), and ApcT ([@B53]).

Later, new crystal structures of LeuT have provided some insight into how inhibitors and antidepressants might bind to this bacterial transporter ([@B57], [@B56]; [@B67], [@B68]; [@B41]). Crystal structures of LeuT co-crystallized with the inhibitor tryptophan showed two tryptophan molecules bound, one in S1 and the other in the extracellular vestibule, also known as the S2 site. In comparison to LeuT crystal structures with bound substrate, such as alanine or leucine, the Trp-LeuT complex has the protein in an outward-open conformation in which the solvent has access to the substrate molecule in S1, caused by a rotation of the two aromatic residues, otherwise guarding the substrate binding site, and a small tilt in TM4 ([@B56]). Several structures of LeuT have later confirmed the presence of the S2 site in the outer vestibule, and they show that many different types of molecules can bind here, e.g., detergents ([@B41]) and inhibitors, such as the amino acid tryptophan ([@B56]) as well as antidepressants ([@B57]; [@B67], [@B68]). The relevance of these binding models in relation to how the human BATs are being inhibited has, however, been strongly debated ([@B45]; [@B39]; [@B40]).

The first high-resolution insight to drug binding to the BATs was elucidated in 2013 through the publication of crystal structures of engineered LeuT, LeuBAT ([@B62]), and the *Drosophila* DAT (dDAT; [@B38]). LeuBAT is an engineered version of LeuT where the key residues within the central binding site have been mutated to resemble the pharmacology of the BATs. Twelve structures of LeuBAT with various antidepressants co-crystallized were published. The structures included LeuBAT in complex within selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs) with varying amount of point mutations (Δ5, Δ6, and Δ13). The crystal structures included the binding of mazindol in the Δ5 and Δ6 structures, whereas seven structures were obtained in the Δ13 LeuBAT including the binding of the TCA clomipramine (CMI; [@B62]). The dDAT structure published in 2013 contained the TCA nortriptyline within the central binding site ([@B38]) in the same binding mode as found for CMI in LeuBAT ([@B62]), revealing that the previous LeuT crystal structures with co-crystallized antidepressants in the S2 site most likely do not reflect the relevant binding mode of these drugs in the BATs.

Importantly, in May 2015 an arsenal of new crystal structures of dDAT with various ligands bound were published ([@B37]; [@B63]). These new crystal structures included the substrate DAT, the psychostimulants *D*-amphetamine, (+)-methamphetamine, cocaine and the cocaine analog RTI-55 as well as SNRIs, NET-specific reuptake inhibitors (NRIs) and SSRIs bound. For the first time it is accordingly possible to directly compare the binding of substrates to that of different types of inhibitors in a DAT structure.

Several models have been published describing the binding of substrates, antidepressants, psychostimulants and mazindol to either of the human BATs using homology models constructed based on the structure of the bacterial homolog LeuT ([@B16]; [@B24]; [@B27],[@B28]; [@B5]; [@B7]; [@B25]; [@B4], [@B2], [@B3]; [@B23]; [@B61]; [@B9]; [@B20]; [@B32], [@B31], [@B29],[@B30]; [@B48]; [@B58]; [@B49]; [@B54]; [@B35]; [@B52], [@B51]; [@B10]; [@B65]).

Herein, we compare the binding of drugs to dDAT ([@B38]; [@B63]) and LeuBAT ([@B62]) obtained from the crystal structures to previously built homology models that have been constructed based on the bacterial homolog LeuT ([@B66]). The comparison clearly illustrates that it is possible to predict the binding of drugs to the human BATs through carefully calculated computer models in combination with experimental validation.

Comparison Between dDAT, LeuBAT, and Homology Models of Human BATs
==================================================================

Substrate Binding
-----------------

The structure of the dDAT protein compared to a homology model of the human DAT previously published ([@B30]) is shown in Figure [1A](#F1){ref-type="fig"}. The general agreement between the homology model of hDAT and the crystal structure of dDAT is very good and the principal differences are observed within TM12, which is slightly kinked in the dDAT structure. One of the largest differences observed between LeuT and dDAT is also TM12 as described previously ([@B38]) and the differences observed here is therefore not surprising since the hDAT model has been based on the LeuT structure, in which TM12 is not kinked.

![**Similarities in dDAT and hDAT structures and substrate binding. (A)** The overall structure of dDAT ([@B63]) and the homology model of hDAT ([@B30]) based on an outward occluded LeuT structure are almost identical with the largest difference being in TM12 where a kink is observed within the dDAT structure. **(B)** Comparison of the binding mode of the substrate dopamine (DA) within the dDAT crystal structure (gray; [@B63]) and two binding modes obtained from modeling ([@B30]) shown in light and dark blue. Italic residue numbers are from the hDAT homology model and normal labels belong to dDAT. **(C)** Comparison of the binding mode of the substrate DA within the dDAT crystal structure (gray; [@B63]) and the substrate norepinephrine (NE) in two binding modes obtained from homology model of hNET ([@B30]) with the models shown in light and dark green. Italic residue numbers are from the hNET homology model. **(D)** Comparison of the binding mode of the substrate DA within the dDAT crystal structure (gray; [@B63]) and the substrate serotonin (5-HT) in the experimental validated binding mode within a homology model of hSERT ([@B30]) with the model shown in pink. Italic residue numbers are from the hSERT homology model.](fphar-06-00208-g0001){#F1}

The homology models of hDAT, hNET, and hSERT are compared with the dDAT crystal structure by alignment of the central binding site residues (Figure [1](#F1){ref-type="fig"}). For the alignment, residues within 5 Å of the co-crystallized nortriptyline in the dDAT structure are selected ([@B38]). The residues used from dDAT are S320, F319, L321, D46, G322, A44, F43, F325, S421, V327, G425, S426, S422, A117, D121, I116, V120, Y123, Y124, A479, and the Cα atoms of the corresponding residues within the other transporters based on structural and sequence alignment ([@B6]). The location of the DAT substrate within dDAT from the crystal structure strongly resembles the location of DAT proposed by [@B30]; Figure [1B](#F1){ref-type="fig"}) and also proposed by others ([@B5]; [@B54]). The position of the binding site residues is also very similar with only small deviations at a few positions. Similarly the binding of NET in hNET obtained by homology modeling ([@B30]) strongly resembles the position of the very similar substrate DAT within dDAT (Figure [1C](#F1){ref-type="fig"}). Additionally the experimental validated orientation of SERT within hSERT ([@B7]) overlay with the position of DAT within dDAT (Figure [1D](#F1){ref-type="fig"}). There are accordingly excellent agreements between the substrate-bound dDAT structure and the substrate binding modes predicted based on homology modeling ([@B5]; [@B7]; [@B31], [@B30]; [@B49]; [@B54]).

Psychostimulants Binding
------------------------

Since drug addiction is an enormous burden to society and human health, it is extremely important to understand the molecular mechanism of how these compounds interact with the BATs. Drugs of abuse include inhibitors like cocaine and a class of compounds such as amphetamine, which are able to reverse the direction of transport in BATs by a mechanism that is still not fully understood. This class of molecules is termed "releasers" and includes amphetamine, methamphetamine and some phenyl-piperazine (PP) derived compounds. The binding of PP and an analog has been studies computationally using homology models of hDAT and hSERT ([@B52]). The recently published crystal structure of dDAT included structures that have *D*-amphetamine and (+)-methamphetamine bound ([@B63]). In Figure [2A](#F2){ref-type="fig"} an overlay of the two releasers from the crystal structures are displayed along with the position of PP within a hDAT model ([@B52]). As can be observed, there is a pronounced agreement with the position of the releasers within the S1 binding site of DAT. The orientation of PP in hDAT has been observed to be identical to the one observed within hSERT and similar to the orientation of the substrate SERT ([@B52]). The binding of amphetamine described by [@B5] additionally shows this same orientation of amphetamine to a hDAT homology model ([@B5]). This could indicate that the substrates and releasers, which are all expected to be transported by the BATs, occupy a similar space within the central binding site and that the orientation is conserved amongst the BATs.

![**Comparison of psychostimulants, mazindol and antidepressant binding between the dDAT and LeuBAT crystal structures and human BAT homology models. (A)** Comparison of releaser binding. *D*-amphetamine (gray) and (+)-methamphetamine (light brown) from dDAT crystal structures ([@B63]) and PP (cyan) within a hDAT homology model ([@B52]). hDAT labels are shown in italic. **(B)** Comparison of cocaine and analogs binding. Cocaine (light gray) and RTI-55 (white) from dDAT crystal structures ([@B63]) and cocaine (yellow) within a hSERT homology model ([@B29]). hSERT labels are shown in italic. **(C,D)** Comparison of NRI and SSRI binding. **(C)** Nisoxetine (gray) and reboxetine (light purple) from dDAT crystal structures ([@B37]) and *S*-citalopram (green) within a hSERT homology model ([@B32]). hSERT labels are shown in italic. **(D)** Sertraline (light gray), *R*-fluoxetine (orange), paroxetine (yellow), fluvoxamine (purple) within LeuBAT crystal structures ([@B62]) and nisoxetine (blue) within dDAT ([@B37]) compared to *S*-citalopram (green; [@B32]) and *R*-fluoxetine (brown; [@B3]) from hSERT homology models. LeuBAT labels are shown in normal font, dDAT labels are underlined and hSERT labels are shown in italic. **(E)** Comparison of mazindol binding. Mazindol in LeuBAT crystal structure (white; [@B62]). Mazindol binding to a hDAT homology model (light purple) and a hSERT homology model (dark purple; [@B51]). hDAT labels are underlined and hSERT labels are italic. The view has been rotate 180 degrees compared to **(A--D)**. **(F)** Comparison of the tricyclic antidepressant binding. Clomipramine (white) in LeuBAT crystal structure ([@B62]). Imipramine (light orange) and 3-cyano imipramine (dark orange) binding to a hSERT homology model ([@B58]). hSERT labels are italic. The view has been rotate 180 degrees compared to **(A--D)**.](fphar-06-00208-g0002){#F2}

The binding of cocaine has previously been studied through homology modeling both of hDAT ([@B5]) and hSERT ([@B29]). An overlay of the recently published crystal structures of dDAT with cocaine and the cocaine analog RTI-55 ([@B63]) and the binding model of cocaine in hSERT ([@B29]) is seen in Figure [2B](#F2){ref-type="fig"}. Again we observe that the computer models are able to predict the binding of molecules to hSERT and that the orientation and overall position is the same in the model and the crystal structure with a small displacement of the N^+^ group, most likely caused by subtle differences of the phenylalanine within the aromatic lid. The overall location of cocaine in [@B5] is additionally similar to what is also observed in the dDAT crystal structure, further supporting that homology models are indeed able to be predictive of drug binding to proteins. Additionally, the benztropine JHW007 ([@B12]) has been shown to occupy the same site as cocaine within DAT ([@B5]) indicating that benztropines could bind in a similar fashion as cocaine in the dDAT structure.

Binding of Antidepressants and Mazindol
---------------------------------------

The binding of the SSRI *S*-citalopram was previously biochemically validated to bind in the central S1 site of hSERT ([@B32]). The recently published dDAT structures by [@B37] has revealed that the NRIs nisoxetine and reboxetine bind to the central binding site of dDAT. Figure [2C](#F2){ref-type="fig"} illustrates that the SSRI *S*-citalopram and the NRIs nisoxetine and reboxetine occupy the same space within the central binding pocket as assessed by comparing the hSERT homology model ([@B32]) and the dDAT crystal structures ([@B37]). The pharmacology profile of dDAT resembles that of hNET more than hDAT which could suggest that the orientation of NRIs in dDAT is representative of binding to hNET. This further hints to SSRIs and NRIs as possibly binding in a similar fashion in hSERT and hNET respectively.

Numerous SSRIs have been co-crystallized with the LeuBAT structures ([@B62]). Figure [2D](#F2){ref-type="fig"} illustrates the overlay between SSRIs bound to LeuBAT and the SSRIs fluoxetine ([@B3]) and *S*-citalopram ([@B32]) within a hSERT homology model in addition to nisoxetine bound to dDAT ([@B37]). Again we see high degree of overlap in spatial orientation of these antidepressants within the central binding site. Some discrepancies are observed between the binding of fluoxetine (Prozac) obtained through modeling ([@B3]) and a LeuBAT crystal structure ([@B62]; Figure [2D](#F2){ref-type="fig"}). As discussed in details in [@B3] this difference in orientation of the large antidepressant fluoxetine in the model and the engineered LeuBAT can potentially be assigned to the fact that the LeuBAT structure is only partly representing the binding site of hSERT.

Mazindol has been shown to be an anorectic agent ([@B1]) and like cocaine, mazindol binds to all human BATs. The LeuBAT structures published in 2013 revealed the binding of mazindol both to the Δ5 and the Δ6 structures ([@B62]). In both structures mazindol was found in the same orientation. A comparison of the binding of *R*-mazindol in the Δ6 LeuBAT crystal structure ([@B62]) with the mode obtained through homology modeling and docking in a hSERT and a hDAT model ([@B51]) is seen in Figure [2E](#F2){ref-type="fig"}. We observe excellent agreement between the binding modes obtained through the computational studies and the crystal structure of the engineered LeuT protein. Only a small reorientation of the chlorophenyl group is observed between the two crystal structures and the models.

Lastly we have compared the binding mode of TCAs between the LeuBAT structure ([@B62]) and models obtained through computational studies ([@B58]). The TCA CMI was co-crystallized in the Δ13 LeuBAT structure ([@B62]). The first dDAT structure was also crystallized with a TCA, nortriptyline, and the orientation of this drug is the same in dDAT as CMI in LeuBAT ([@B38]; [@B62]). The binding of the TCA imipramine and analogs binding to a hSERT homology model has previously been explored ([@B4]; [@B48]; [@B58]). We observe that the tricyclic ring structure of the antidepressants overlays within the central binding site of hSERT ([@B58]) and LeuBAT ([@B62]). Additionally both the 3-position chlorine substituent in CMI from the crystal structure and 3-cyano imipramine within the hSERT model are orientated toward the aromatic lid of the central binding site (Figure [2F](#F2){ref-type="fig"}). Again, this illustrates excellent agreement between computational models and subsequent crystal structures as seen both for LeuBAT and dDAT.

Discussion
==========

We have displayed excellent agreement between the binding modes of numerous types of ligands to homology models of the human BATs and crystal structures of dDAT and the engineered LeuBAT. We have explored and compared the binding of several classes of ligands ranging from the substrates over psychostimulants, including the releasers PP and amphetamines and the inhibitor cocaine, SSRIs, NRIs, to the anorectic drug mazindol and the TCA imipramine and analogs. Binding of several other compounds to BATs has been studied computationally including the anti-abuse drug ibogaine ([@B29]) and SERT-binding fluorescent drugs ([@B65]), however, these still remain to be elucidated by high-resolution structures. The agreement between the crystal structures and computational models illustrate that it is possible to obtain informative and useful models of drug binding to homology models through careful modeling in conjugation with experimental validation. Particularly the structures of dDAT has opened up for a great revenue to use in the exploration of drug binding, while LeuBAT has additionally shown to be illustrative of drug binding modes in the case of SSRIs, mazindol and TCAs.

Interestingly, in the novel structures of dDAT one of the significant conformational changes between an occluded and outward facing state is the rotation of the aromatic lid residues F319 (equivalent to F253 in LeuT, F335 in hSERT, F320 in hDAT, and F317 in hNET). A large number of published homology models of the human BATs ([@B7]; [@B32], [@B31], [@B29],[@B30]; [@B58]; [@B52], [@B51]; [@B3]) have been constructed based on the first crystal structure of LeuT which was found in an outward occluded state ([@B66]). Not surprisingly, the largest difference in the binding site residues between the homology models and the dDAT crystal structures are accordingly the position of the phenylalanine within the aromatic lid (F317 in dDAT; F335 in hSERT, F320 in hDAT, and F317 in hNET) as seen in Figures [1B](#F1){ref-type="fig"}--[D](#F1){ref-type="fig"} and Figures [2A](#F2){ref-type="fig"}--[D](#F2){ref-type="fig"}.

We observe that the early models of the human BATs constructed based on the bacterial homolog LeuT are in excellent agreement with the subsequent crystal structures, but importantly to note is that these predictions require careful selection of ligand binding modes combined with the consideration of more than top docking poses. This provides us with great confidence in the ability to use extensive modeling combined with experimental validations to provide initial insight to drug binding to proteins. Although the computational docking models are able to predict the binding of compounds to the BATs, a substantial limitation of the static models is the inability to predict the difference in function between the drugs. To understand the function, non-static methods such as molecular dynamics simulations ([@B29]; [@B21]) or electron paramagnetic resonance (EPR; [@B8]) need to be applied.

The dDAT structure has been seen to possess a pharmacology profile resembling hNET more than dDAT ([@B37]) which should equally be taken into consideration when interpreting the dDAT structure. Nevertheless, current advances not only in computational models and more recently high resolution information from crystal structures have allowed us to move one step closer to understanding how drugs binding to the pharmaceutically important BATs.
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